China FDA notes meeting with U.S. counterparts, but no details

SINGAPORE--China and U.S. drug officials held their first working meeting of the year recently, China's FDA revealed, but it offered no information other than the general matters discussed.

A short China FDA notice said the two agencies discussed inspections for good manufacturing practices carried out last year, their bilateral cooperation in high-level meetings and the year's personnel exchanges. They also "discussed the tasks of 2015," the notice said.

The discussions, which were held Feb. 11, were attended by officials of the CFDA's Department of International Cooperation and the U.S. FDA's China office.

- read the CFDA notice here

Related Stories:
FDA Commissioner to talk drug safety with top Chinese officials
FDA bans maker of suspect Chinese heparin
The FDA is stationing 10 new drug inspectors in China

Suggested Articles

New legal complaints focus on eight Sanofi executives, most of them with local management titles, and 15 managers at distributor Zuellig Pharma.

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

A decree includes tax incentives for certain generic drugmakers and uniform insurance standards that apply to both branded drugs and generics.